The NeuroCytotron utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells ROCKVILLE, Md. , Jan. 30, 2023 /PRNewswire-PRWeb/ -- NeuroCytonix, Inc. (the "Company" or ...
FinancialNewsMedia.com News Commentary PALM BEACH, Fla. , Jan. 19, 2023 /PRNewswire/ -- Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based ...
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI , Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has ...
Patients sustained significant improvement in signs and symptoms up to 20 weeks after medication was stopped NEW YORK , Dec. 9, 2022 /PRNewswire-PRWeb/ -- Patients with moderate to severe atopic dermatitis who participated in a clinical ...
SUZHOU, China , Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the ...
The majority of Clinical & Quality leads at Pharma, Biotech and CROs are largely positive about the one-stop portal, which promises to make Europe a more attractive and cohesive market in which to conduct trials. 40% have already submitted ...
Phase 1 clinical study demonstrated PK bioequivalence and comparable safety and immunogenicity profiles between BFI-751 and reference Stelara® FREDERICK, Md. , Oct. 14, 2022 /PRNewswire-PRWeb/ -- BioFactura Inc. has announced today the ...
Data p rovide first clinical proof of mechanism of action and clinical utility of NMD Pharma's lead asset NMD670 in Myasthenia Gravis The clinical validation provides a unique translational platform and informs ...
First of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md. , Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development ...
Continuous subcutaneous infusion (CSCI) of levodopa/carbidopa prodrugs, foslevodopa/foscarbidopa, improved time without dyskinesia in patients with advanced Parkinson's disease (PD) according to a phase 3 clinical trial released today at the ...
Bharat Biotech, in collaboration with Biofabri, a Spanish biopharmaceutical firm, is conducting trials for the first live attenuated vaccine MTBVAC ( ) derived from a human strain of Mycobacterium tuberculosis. These trials aim to assess the safety and ...
A multisite clinical trial offers promising outcomes for patients with metastatic and recurrent uterine cancer, also known as endometrial cancer. Presented at the annual meeting of the Society of Gynecologic Oncologists, the study compiled data from ...
Researchers at the University of Oxford in the UK have initiated the first human clinical trial to evaluate ChAdOx1 NipahB vaccine designed to safeguard individuals against the deadly Nipah virus . ( ) ChAdOx1 NipahB Vaccine Trial with 51 Participants to Combat Nipah Virus Threat Fifty-one people aged 18 to 55 will participate in the ...
The stromal processing peptidase (SPP), a chloroplast plant enzyme, reduces the clumping of proteins that cause the pathogenic alterations in models of Huntingtons disease in human cells and the nematode Caenorhabditis elegans ( ). ...
A group of US researchers, who first conducted an ‘ artificial womb ’ experiment in lamb, are now seeking Food and Drug Administration (FDA) approval for its tests on humans ( ). This could potentially reduce deaths and disability for babies ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers